PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER

PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER

Pharmaceutical Combination for the Treatment of Cancer The present invention relates to combinations of at least two components, component A and component B for use in the treatment of cancer, component A being an anti-CEACAM6 antibody and component B being an anti-PD-1 antibody, preferentially nivo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BECKHOVE, Philipp, WILLUDA, Jörg, OFFRINGA, Rienk, TRAUTWEIN, Mark, BÖHM, Hans-Henning
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pharmaceutical Combination for the Treatment of Cancer The present invention relates to combinations of at least two components, component A and component B for use in the treatment of cancer, component A being an anti-CEACAM6 antibody and component B being an anti-PD-1 antibody, preferentially nivolumab, or pembrolizumab, or an anti-PD-L1 antibody, preferentially atezolizumab, avelumab, or durvalumab.